Eicosanoid Regulation of Macrophage-Mediated Anti-Tumor Function

  • Iván L. Bonta
  • Graham R. Elliott
  • Shlomo Ben-Efraim
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 177)


When phospholipids deliver free arachidonic acid (AA), it can be in macrophages metabolized either into the cyclooxygenase pathway or into lipoxygenase products. The release of eicosanoids is intimately related to the activation state of macrophages. The production of the cyclooxygenase metabolite PGE2 is inversely correlated with the activation state. Furthermore PGE2, via receptor-mediated activation of adenylate cyclase, is involved in elevated levels of intracellular cyclic AMP in macrophages. Increased levels of cyclic AMP are associated with inhibition of macrophage functions and PGE2 which activates the adenylate cyclase, is recognized as deactivator of macrophages. In this context, inhibitors of cyclooxygenase promote the activation of macrophages, as i.a. shown by enhanced release of lysosomal enzymes (Schenkelaars & Bonta 1986). In contrast to the above, the lipoxygenase pathway favours the activation of macrophages. Several immunological events are associated with increased biosynthesis of leukotrienes (LTs) (Rola-Pleszczynski & LeMaire 1986). Macrophages were shown to be responsive to exposure of either LTC4 or LTD4, both of them inducing the release of several products of the cyclooxygenase pathway. Using the secretion of a lysosomal enzyme as a marker of cell activity, LTC4 was also shown to trigger the activation of macrophages. Thus LTC4 proved to enhance the enzyme secretion of macrophages, whereas PGE2 inhibited this event. Because lysosomal enzyme release was observed with a lower concentration of LTC4 than necessary to induce the biosynthesis of PGE2 it was proposed that the enzyme secretion is the primary event and that the subsequent release of PGE2 serves to limit the activating function of the peptidoleukotriene. In that case full expression of LT induced activation would only be observed in the absence of endogenous, PGE2. Indeed, it was shown that inhibitors of cyclooxygenase promote the LTC4-induced release of a lysosomal enzyme (Schenkelaars & Bonta 1986). The finding that LTs promote the production of PGE2, — the cyclooxygenase metabolite which suppresses macrophages — indicates that the action of LTs is self-limiting and that eicosanoid formation is, at least partially, regulated by interactions between the different metabolites of AA. The more recent observation, showing that the calcium flux-induced release of LTB4 is counteracted by PGE2 and augmented by inhibitors of cyclooxygenase (Elliott et al. 1988b), gives further support to the concept that the dynamic state of activation of macrophages is maintained by balanced interactions between endogenous PGE2 and leukotrienes. Macrophage cytotoxicity or cytostasis towards tumor cells is a characteristic expression of macrophage activation. Studies, which were aimed to investigate the role of eicosanoids in the anti-tumor function of macrophages, represented a logical move.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams, D. O., and Hamilton, T. A., 1984, The cell biology of macrophage activation. Am. Rev. Immunol., 2: 283.CrossRefGoogle Scholar
  2. Bouta, I. L., and Ben-Efraim, S., 1987, Leukotrienes and prostaglandins mutually govern the antitumor potential of macrophages. In: “Prostaglandins in Cancer Research”, M. G. Santoro, ed., Springer Verlag pp. 193–201.Google Scholar
  3. Dinarello, C. A., Cannon, J. G., Mier, J. W., Bernheim, H.A., LoPreste, G., Lynn, D. L., Love, R. N. Well, A. C., Auron, P. E. Ruben, R. C., Rich, A., Wolff, S. M., and Putney, S. D., 1986, Multiple biological activities of human recombinant interleukin-1. J. Clin. Invest., 77: 1734.Google Scholar
  4. Elliott, G. R., Tak, C., Pellens, C., Ben-Efraim, S., and Bouta, I. L., 1988a, Indomethacin stimulation of macrophage cytostasis against MOPC-315 tumor cells is inhibited by both prostaglandin E2 and nordihydroguaiaretic acid, a lipoxygenase inhibitor. Cancer Immunol. Immunother., 27: 133.Google Scholar
  5. Elliott, G. R., Lauwen, A. P. M., and Bonta, I. L., 1988b, Prostaglandin E2 inhibits and indomethacin and aspirin enhance, A23187-stimulated leukotriene B4 synthesis by rat peritoneal macrophages. Br. J Pharmac., 96: 265.Google Scholar
  6. Elliott, G. R. Tak, C., and Bonta, I. L., 1988c, Prostaglandin E2 enhances, and leukotriene C4 inhibits, interleukin-1 inhibition of WEHI-3B cell growth. Cancer Immunol. Immunother., 28: 74.Google Scholar
  7. Farrar, W. L., and Humes, J. L., 1985, The role of arachidonic acid metabolism in the activities of interleukin-1. J. Immunol., 135: 1153.PubMedGoogle Scholar
  8. Hilten, J. A. van, Elliott, G. R., and Bonta, I. L., 1988, Specific lipoxygenase inhibition reverses macrophage cytostasis towards P815 tumor cells in vitro induced by the calcium ionophore A23187. Prostaglandins, Leukotrienes and Fatty Acids, 34: 187.Google Scholar
  9. Kunkel, S. L., Chensue, S. W., and Phan, S. H., 1986, Prostaglandins as endogenous modulators of interleukin-1 production. J. Immunol. 136: 186.PubMedGoogle Scholar
  10. Leibovici, J., Hoenig, S., and Pinchassov, A., 1986, In vitro effect of levan-activated macrophages on Lewis lung carcinoma cells. Int. J. Immunopharmac., 8: 471.Google Scholar
  11. Matthews, N., 1981, Production of an anti-tumor cytotoxin by human monocytes. Immunol., 44: 135.Google Scholar
  12. Nathan, C. F., Arrick, B. A., Murray, H. W., Desantis, N. M., and Cohn, Z. A., 1980, Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J. Exp. Med., 153: 766.CrossRefGoogle Scholar
  13. Onozaki, K., Matsushima, K., Aggarwai, B. B., and Oppenheim, J. J., 1985, Human interleukin-1 is a cytocidal factor for several tumor cell lines. J. Immunol., 135: 3962.PubMedGoogle Scholar
  14. Ophir, R., Ben-Efraim, S., and Bonta, I. L., 1987, Leukotriene D4 and indomethacin enhance additively the macrophage cytostatic activity in vitro towards MOPC-315 tumor cells. Int. J. Tiss. Reac., 9: 189.Google Scholar
  15. Rola-Pleszczynski, M., and LeMaire, I., 1985, Leukotrienes augment interleukin-1 production by human monocytes. J. Immunol., 135: 3958.PubMedGoogle Scholar
  16. Schenkelaars, E. J., and Bonta, I. L., 1986, Cyclooxygenase inhibitors promote the leukotriene C4 induced release of beta-glucuronidase from rat peritoneal macrophages: Prostaglandin E2 suppresses Int. J. Immunopharmac., 8: 305.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Iván L. Bonta
    • 1
  • Graham R. Elliott
    • 1
  • Shlomo Ben-Efraim
    • 2
  1. 1.Dept. of Pharmacology, Faculty of MedicineErasmus Univ. RotterdamRotterdamThe Netherlands
  2. 2.Dept. of Human Microbiology, Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations